EMA/PE/0000227674 - paediatric investigation plan

zampilimab

Key facts

• Active substance:
  zampilimab
• Therapeutic area:
  Respiratory, thoracic and mediastinal disorders
• Decision number:
  EMA/PE/0000227674
• PIP number:
  EMA/PE/0000227674
• Pharmaceutical form(s):
  Solution for infusion
• Condition(s) / indication(s):
  Treatment of idiopathic pulmonary fibrosis
• Route(s) of administration:
  Intravenous use
• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  03/01/2025
• Compliance check done:
  No

Decision

EMA/PE/0000227674 : EMA decision of 3 January 2025 on the granting of a product specific waiver for zampilimab

Adopted Reference Number: EMADOC-1700519818-1802286